Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study

British Medical Journal

Volumn 330, Issue 7489, 2005, Pages 445-448

  Gill, Sudeep S ^a,i   Rochon, Paula A ^b   Herrmann, Nathan ^c   Lee, Philip E ^f   Sykora, Kathy ^a   Gunraj, Nadia ^a   Normand, Sharon Lise T ^g   Gurwitz, Jerry H ^h   Marras, Connie ^d   Wodchis, Walter P ^e   Mamdani, Muhammad ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e TORONTO REHABILITATION INSTITUTE   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ St Mary's of the Lake Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIOPROPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY RISK; DEMENTIA; HAZARD ASSESSMENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS; STROKE;

AGED; ANTIPSYCHOTIC AGENTS; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; DEMENTIA; HOSPITALIZATION; HUMANS; INCIDENCE; ONTARIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 20044375721     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38330.470486.8F     Document Type: Article

References (28)

1. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. I: a conceptual review. J Am Geriatr Soc 1998;36:7-12.
2. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
3. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106-12.
4. Health Canada, important drug safety information: RISPERDAL* (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials - Janssen-Ortho. www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/risperdall_e.html (accessed 15 Nov 2004).
5. Brodaty H, Ames D, Snowden J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo controlled trial of risperidone for the treatment of aggression, agitadon, and psychosis in dementia. J Clin Psychiatry 2003;64:134-43.
6. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CAMJ 2002;167:1269-70.
7. 2003 Safety alert: RISPERDAL (risperidone). Washington, DC: US Food and Drug Administration; 1 Mar 2004. www.fda.gov/medwatch/SAFETY/2003/risperdal.htm (accessed 15 Nov 2004).
8. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395.
9. Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines (CEM/CMO/2004/1). www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/antipsystroke_9304.htm (accessed 15 Nov 2004).
10. Gladstone DJ, Kapral MK, Fang J, Laupacis A, Tu JV. Management and outcomes of transient ischemic attacks in Ontario. CMAJ 2004;170:1099-104.
11. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000;284:2901-6.
12. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328:326-8.
13. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004;62:2015-20.
14. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002;288:1388-95.
15. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
16. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic therapy in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75-8.
17. Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MM. Incidence, risk, and case fatality of first ever stroke in the elderly population: the Rotterdam study. J Neurol Neurosurg Psychiatry 2003;74:317-21.
18. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161:1113-5.
19. Liperoti R. Cerebrovascular events among elderly patients treated with conventional or atypical antipsychotics. 2004 Annual meeting of the American Geriatrics Society. www.americangeriatrics.org/news/meeting/schedule_events.pdf (accessed 15 Nov 2004).
20. Kozma CM, Engelhart LM, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. 2003 meeting of the International College of Geriatric Psychoneuropharmacology. www.icgp.org/ ICGP_2003_program_Book.pdf (accessed 15 Nov 2004).
21. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004;5:129-32.
22. Wallaschofski H, Donne M, Eigenthaler M, Hentschel B, Faber R, Stepan H, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001;86:5912-9.
23. Harrison-Woolrych M, Clark DWJ. Nose bleeds associated with use of risperidone. BMJ 2004;328:1416.
24. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000;356:1219-23.
25. Brown TM, Boyle MF. Delirium. BMJ 2002;325:644-7.
26. Teri L, Logsdon RG, McCurry SM. Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am 2002;86:641-56.
27. Guidance for the management of behavioural and psychiatric symptoms in dementia and the treatment of psychosis in people with history of stroke/TIA. Working group for the Faculty of Old Age Psychiatry RCPsych, RCGP, BGS, and Alzheimer's Society, following CSM restriction on risperidone and olanzapine. www.bgs.org.uk/publications/CSM%20anouncement%2009%2003%202004.pdf (accessed 15 Nov 2004).
28. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S. National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial methodology. Am J Geriatr Psychiatry 2001;9:346-60.